A systematic review and meta-analysis of 19 studies involving 1,290 patients revealed that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) effectively address suboptimal initial clinical response and weight gain recurrence after bariatric surgery. Notable results included pooled total weight loss percentages of 9.24% for liraglutide, 11.38% for semaglutide, and 15.50% for tirzepatide after three months, alongside significant reductions in various biochemical markers. Adverse events were relatively mild and led to a low discontinuation rate of 3%.
Journal Article by Nie Y, Zhang Y, Liu B and Meng H in Obes Surg
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.